Maxion, Ampersand, Latigo, Arbor raise private rounds: Finance Report

Four biotechs closed rounds totaling more than $360 million this week, with two moving toward their first human studies and two drawing crossover cash to support ongoing clinical trials.

U.K.-based Maxion Therapeutics Ltd. said it had closed a $72 million (£58 million) series A round to develop therapies based on its KnotBody platform. The start-up is aiming to fuse engineered cysteine knots, or knottins, into loops to form antibodies that may be able to bind previously intractable targets, with the goal of treating ion channel or GPCR-mediated diseases...